Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Robbie Stephens Cuts Affymetrix Rating


Robertson Stephens downgraded Affymetrix (AFFX ) to market perform from buy.

Analyst Michael King says the shortfall is due to slackening demand from consolidation in the pharmaceutical industry and softening in the do-it-yourself spotters. He slashed the $240.5 million 2001 product sales estimate to $180.5 million as management expects two to three quarters of limited visibility. He sees $287.5 million 2002 total revenues and now projects the company to breakeven one year later in Q4 2002. King believes the company remains the dominant player in the gene

expression micro-array market, but the shares will be dead money until visibility of an upturn in chip and instrument sales become more apparent later this year.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus